此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

内分泌紊乱、更年期与2型糖尿病女性睡眠质量差:对心血管健康的影响 (EMPOWER)

2026年11月2日 更新者:Ottawa Heart Institute Research Corporation

EMPOWER aims to determine the overall effect of menopause and sleep disruption on cardiac remodeling in women with type 2 diabetes.

研究概览

地位

尚未招聘

详细说明

The EMPOWER prospective cohort study is part of a larger project. This interdisciplinary project will utilize animal models, clinical cohorts, epidemiological datasets and data from randomized control trials to explore the hypothesis that sleep disruption and menopause-induced hormonal changes synergistically increase systemic inflammation and impair incretin signaling, leading to worsened cardiac function, heightened cardiometabolic dysfunction, and accelerated CVD risk.

The EMPOWER study aims to determine the cumulative effect of multiple exposures including menopause progression and sleep disruption on subclinical cardiac remodeling in women with T2DM in the perimenopausal transition and if these relationships are moderated by T2DM management, Body Mass Index (BMI), or inflammation.

研究类型

观察性的

注册 (估计的)

381

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

48年 至 58年 (成人)

接受健康志愿者

不

有资格学习的性别

女性

取样方法

非概率样本

研究人群

The study population will be selected from patients at the University of Ottawa Heart Institute, The Ottawa Hospital, and from within the Ottawa and surrounding area community.

描述

Inclusion Criteria:

  • Female Sex
  • Age range 48-58 years
  • In menopausal transition phase (pre-menopause or peri-menopause)
  • Diagnosis of Type 2 Diabetes Mellitus
  • Have access to and regularly use a smartphone with internet access

Exclusion Criteria:

  • Male Sex
  • Currently Pregnant
  • Prior history of total hysterectomy or bilateral oophorectomy
  • Prior diagnosis of any of the following:

Coronary Vascular Disease (CVD) including coronary heart disease, heart failure, congenital heart disease stroke/transient ischemic attack, valvular heart disease, peripheral vascular disease, aortapathy, atrial fibrillation or flutter, other CVD.

- Untreated serious mental illness (e.g, untreated psychosis).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Evaluation

This is a non-randomized study following individuals in perimenopause with type 2 diabetes. The population will follow a 4 evaluation/observation period with associated questionnaires and medical exams, including bloodwork and cardiac echo.

The intervention in this study is the additional clinical evaluations for women with type 2 DM and in perimenopause.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Reduced septal e' velocity
大体时间:Baseline to 4 years.

Indicates impaired relaxation of the left ventricle during early diastole; key marker for diastolic dysfunction. Measured by echocardiography.

Baseline to 4 years.
Increased E/e' ratio
大体时间:Baseline to 4 years.

Indicates elevated left ventricular filling pressure; key marker for diastolic dysfunction. Measured by echocardiography.

Baseline to 4 years.
Increased tricuspid regurgitation (TR) velocity
大体时间:Baseline to 4 years.

Indicates elevated right ventricular systolic pressure or pulmonary hypertension. Measured by echocardiography.

Baseline to 4 years.
Change in pulmonary artery systolic pressure (PASP)
大体时间:Baseline to 4 years.

Measures the pressure in the pulmonary artery when the heart beats. Measured by echocardiography.

Baseline to 4 years.
Change in E/A ratio
大体时间:Baseline to 4 years.

Decrease of E/A ratio below 1 indicates diastolic dysfunction, and an increase of E/A ratio over 2 indicates advance failure. Measured by echocardiography.

Baseline to 4 years.
Change in left atrial size
大体时间:Baseline to 4 years.

Left Atrial Enlargement (LAE) is abnormal stretching or widening of the upper left heart chamber, typically caused by chronic pressure or volume overload. Measured by echocardiography.

Baseline to 4 years.

次要结果测量

结果测量
措施说明
大体时间
Decline in left ventricular global longitudinal strain (GLS)
大体时间:Baseline to 4 years.

Detects heart muscle dysfunction. Measured by echocardiography.

Baseline to 4 years.
Decline in left atrial strain
大体时间:Baseline to 4 years.

Indicates left ventricular diastolic dysfunction, heart failure with preserved ejection fraction, and atrial fibrillation. Measured by echocardiography.

Baseline to 4 years.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Kerri Anne Mullen, Ph.D.、Ottawa Heart Institute Research Corporation

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2032年12月1日

研究完成 (估计的)

2032年12月1日

研究注册日期

首次提交

2026年3月17日

首先提交符合 QC 标准的

2026年3月17日

首次发布 (实际的)

2026年3月23日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 20260060-01H

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅